{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/ABBV/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T18:18:56.136Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1099,"canonical_name":"AbbVie Inc.","cik":"0001551152","uei":null,"lei":null,"duns":null,"ticker":"ABBV"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":22,"clinical":71,"fda":1,"open":1},"count":95,"timeline":[{"ts":"2026-07-06","kind":"sec.filing","form_type":"8-K","title":"8-K — AbbVie Inc. — 2026-07-06","url_slug":"/sec/cik-0001551152/8-k/0001551152-26-000021","accession_number":"0001551152-26-000021","importance":35},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — RAPP EDWARD J — 2026-07-02","url_slug":"/sec/cik-0001171780/4/0001171780-26-000012","accession_number":"0001171780-26-000012","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-07-02","url_slug":"/sec/cik-0001551152/4/0001997505-26-000008","accession_number":"0001997505-26-000008","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"11-K","title":"11-K — AbbVie Inc. — 2026-06-24","url_slug":"/sec/cik-0001551152/11-k/0001104659-26-077366","accession_number":"0001104659-26-077366","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"SD","title":"SD — AbbVie Inc. — 2026-06-01","url_slug":"/sec/cik-0001551152/sd/0001104659-26-069017","accession_number":"0001104659-26-069017","importance":30},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AbbVie","title":"Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema","security_title":"PHASE2,PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07592273","excerpt":"[\"Diabetic Retinopathy\"]","importance":60},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06972446","excerpt":"[\"Rheumatoid Arthritis\"]","importance":45},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07155174","excerpt":"[\"Small Cell Lung Cancer\"]","importance":45},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06772623","excerpt":"[\"Non Small Cell Lung Carcinoma\"]","importance":45},{"ts":"2026-05-18","kind":"fda.recall","reporter":"AbbVie Inc.","title":"Class III","security_title":"PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product of France, NDC 11980-174-10.","excerpt":"Failed Stability Specifications","accession_number":"D-0551-2026","status":"Ongoing","product_type":"drug","importance":25},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting","security_title":null,"status":"RECRUITING","accession_number":"NCT05094128","excerpt":"[\"Axial Spondylarthritis (r-axSpA)\"]","importance":25},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT05652205","excerpt":"[\"Functional Constipation (FC)\",\"Chronic Idiopathic Constipation (CIC)\"]","importance":70},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05782907","excerpt":"[\"Ulcerative Colitis\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AbbVie","title":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06158841","excerpt":"[\"Multiple Myeloma\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT04379050","excerpt":"[\"Parkinson's Disease (PD)\"]","importance":70},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT07095452","excerpt":"[\"Multiple Myeloma\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03844048","excerpt":"[\"Chronic Lymphocytic Leukemia\",\"Acute Myeloid Leukemia\",\"Multiple Myeloma\",\"Non-Hodgkin's Lymphoma\",\"Acute Lymphoblastic Leukemia\",\"Cancer\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05995353","excerpt":"[\"Crohn's Disease\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06734351","excerpt":"[\"Mid Face Volume Deficit\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05125302","excerpt":"[\"Migraine\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT07005102","excerpt":"[\"Non-Squamous Non-Small Cell Lung Cancer\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06100744","excerpt":"[\"Juvenile Psoriatic Arthritis\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06417775","excerpt":"[\"Migraine\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06822738","excerpt":"[\"Primary Open Angle Glaucoma\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07071519","excerpt":"[\"Ulcerative Colitis\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06332534","excerpt":"[\"Crohn's Disease\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06696755","excerpt":"[\"Bipolar I Disorder\",\"Bipolar II Disorder\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06890338","excerpt":"[\"Epithelial Ovarian Cancer\",\"Fallopian Tube Cancer\",\"Primary Peritoneal Cancer\",\"Neoadjuvant\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06158854","excerpt":"[\"Immunoglobulin Light Chain (AL) Amyloidosis\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07276997","excerpt":"[\"Major Depressive Disorder\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07387471","excerpt":"[\"Waldenstrom Macroglobulinemia\",\"Lymphoplasmacytic Lymphoma\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05005403","excerpt":"[\"Non-Small Cell Lung Cancer\",\"Head and Neck Squamous Cell Carcinoma\",\"Micro Satellite Stable Colorectal Cancer\",\"Gastric/Esophageal Cancer\",\"High-Grade Serous Ovarian Cancer\",\"Pancreatic Cancer\",\"Triple Negative Breast Cancer\"]","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05650632","excerpt":"[\"Multiple Myeloma\"]","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07291232","excerpt":"[\"Obesity\"]","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Expanded Access to Telisotuzumab Vedotin","security_title":null,"status":"TEMPORARILY_NOT_AVAILABLE","accession_number":"NCT04830202","excerpt":"[\"Non-Small Cell Lung Cancer (NSCLC)\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis","security_title":null,"status":"RECRUITING","accession_number":"NCT07039110","excerpt":"[\"Plaque Psoriasis\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease","security_title":null,"status":"RECRUITING","accession_number":"NCT06965374","excerpt":"[\"Parkinson Disease\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Expanded Access to Elezanumab","security_title":null,"status":"AVAILABLE","accession_number":"NCT04278235","excerpt":"[\"Acute Spinal Cord Injury (SCI)\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT04777357","excerpt":"[\"Depression\",\"Bipolar I Disorder\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06810505","excerpt":"[\"Chronic Migraine\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06241313","excerpt":"[\"Migraine\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06389136","excerpt":"[\"Atopic Dermatitis\"]","importance":60},{"ts":"2026-05-12","kind":"sec.filing","form_type":"8-K","title":"8-K — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/8-k/0001104659-26-059484","accession_number":"0001104659-26-059484","importance":35},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/4/0001563579-26-000002","accession_number":"0001563579-26-000002","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/4/0001706126-26-000002","accession_number":"0001706126-26-000002","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/4/0001916665-26-000002","accession_number":"0001916665-26-000002","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/4/0001997505-26-000006","accession_number":"0001997505-26-000006","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06896916","excerpt":"[\"Multiple Myeloma\"]","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06977724","excerpt":"[\"Dry Eye Syndrome\",\"Systemic Lupus Erythematosus\"]","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis","security_title":null,"status":"RECRUITING","accession_number":"NCT06764706","excerpt":"[\"Ulcerative Colitis\"]","importance":25},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06464692","excerpt":"[\"Colorectal Cancer\"]","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"10-Q","title":"10-Q — AbbVie Inc. — 2026-05-08","url_slug":"/sec/cik-0001551152/10-q/0001551152-26-000017","accession_number":"0001551152-26-000017","importance":45},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"AUSTIN ROXANNE S","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"RAPP EDWARD J","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"WADDELL FREDERICK H","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"FREYMAN THOMAS C","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"Roberts Rebecca B","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"Hart Brett J","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"BURNSIDE WILLIAM H.L.","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"MEYER MELODY B","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"Davis Jennifer L.","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"Quaggin Susan E","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"FALK THOMAS J","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder","security_title":"PHASE2","status":"TERMINATED","accession_number":"NCT05941442","excerpt":"Sponsor terminated due to significant enrollment and study design challenges","importance":80},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05599984","excerpt":"[\"Advanced Solid Tumors\"]","importance":30},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AbbVie","title":"Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04401748","excerpt":"[\"Myelodysplastic Syndrome (MDS)\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07570147","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT06774313","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"AbbVie","title":"A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07567781","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05618028","excerpt":"[\"Diffuse Large B-Cell Lymphoma\",\"Chronic Lymphocytic Leukemia\",\"B Cell Malignancies\",\"Non-Hodgkin's Lymphoma\"]","importance":30},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"AbbVie","title":"Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05978622","excerpt":"[\"Diabetic Macular Edema\"]","importance":25},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06125795","excerpt":"[\"Chronic Lymphocytic Leukemia\"]","importance":25},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07136103","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"AbbVie","title":"Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05843643","excerpt":"[\"Systemic Lupus Erythematosus\"]","importance":60},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07413133","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China","security_title":"PHASE4","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05821855","excerpt":"[\"Open-angle Glaucoma\",\"OAG\"]","importance":25},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"AbbVie","title":"A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07414784","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis","security_title":null,"status":"COMPLETED","accession_number":"NCT04433442","excerpt":"[\"Psoriasis\",\"Psoriatic Arthritis\"]","importance":25},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"AbbVie","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05407636","excerpt":"[\"AMD\",\"nAMD\",\"Wet Age-related Macular Degeneration\",\"wAMD\",\"WetAMD\",\"CNV\"]","importance":60},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease","security_title":"PHASE4","status":"COMPLETED","accession_number":"NCT06346288","excerpt":"[\"Inflammatory Bowel Disease\"]","importance":25},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07539844","excerpt":"[\"Ovarian Cancer\"]","importance":25},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06820463","excerpt":"[\"Metastatic Colorectal Cancer\"]","importance":45},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07525206","excerpt":"[\"Colorectal Cancer\"]","importance":60},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04524611","excerpt":"[\"Crohn's Disease (CD)\"]","importance":60},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06428019","excerpt":"[\"Chronic Lymphocytic Leukemia\"]","importance":60},{"ts":"2026-04-08","kind":"clinical.trial","reporter":"AbbVie","title":"A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT04102020","excerpt":"[\"Acute Myeloid Leukemia (AML)\"]","importance":70},{"ts":"2026-04-08","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06318273","excerpt":"[\"Metastatic Castration-Resistant Prostate Cancer\"]","importance":30},{"ts":"2026-04-07","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07220460","excerpt":"[\"Bipolar I or II Disorder\"]","importance":45},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07024784","excerpt":"[\"Gynecologic Cancers\",\"Platinum-Sensitive Ovarian Cancer\",\"Fallopian Tube Cancer\",\"Primary Peritoneal Cancer (PSOC)\"]","importance":45},{"ts":"2026-04-03","kind":"clinical.trial","reporter":"AbbVie","title":"An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants","security_title":null,"status":"COMPLETED","accession_number":"NCT05827887","excerpt":"[\"Migraine\"]","importance":25},{"ts":"2026-04-01","kind":"clinical.trial","reporter":"AbbVie","title":"Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06548542","excerpt":"[\"Crohn's Disease\"]","importance":45},{"ts":"2026-03-27","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05753501","excerpt":"[\"Hematologic Cancer\"]","importance":30},{"ts":"2026-03-27","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products","security_title":"PHASE4","status":"COMPLETED","accession_number":"NCT06783621","excerpt":"[\"Facial Contouring\"]","importance":25},{"ts":"2026-03-27","kind":"clinical.trial","reporter":"AbbVie","title":"A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting","security_title":null,"status":"RECRUITING","accession_number":"NCT07421258","excerpt":"[\"Crohn's Disease\",\"Ulcerative Colitis\"]","importance":25},{"ts":"2024-12-31","kind":"open.payments","reporter":"ABBVIE INC.","title":"$150310462.0 to 226167 physicians (2024–2024)","security_title":"manufacturer","excerpt":"BOTOX","accession_number":"2024","usd_value":150310462,"importance":70}]}